Výsledky vyhledávání - "Sylvie Sablayrolles"

Protease-Activated Receptor-1 Antagonist F 16618 Reduces Arterial Restenosis by Down-Regulation of Tumor Necrosis Factor α and Matrix Metalloproteinase 7 Expression, Migration, and Proliferation of Vascular Smooth Muscle Cells

Autor: Thierry Bourbon, Sylvie Sablayrolles, Robert Létienne, Stéphane N. Hatem, Michel Perez, Monique David-Dufilho, Anne-Marie Lompré, Pauline Chieng-Yane, Bruno Le Grand, Arnaud Bocquet

Publikováno v: Journal of Pharmacology and Experimental Therapeutics
Journal of Pharmacology and Experimental Therapeutics, American Society for Pharmacology and Experimental Therapeutics, 2011, 336 (3), pp.643-651. ⟨10.1124/jpet.110.175182⟩

Wound healing after angioplasty or stenting is associated with increased production of thrombin and the activation of protease-activated receptor 1 (PAR1). The aim of the present study was to examine the effects of a new selective PAR1 antagonist, 2-

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b4927582b464b95cdc23d3b41c055882
https://doi.org/10.1124/jpet.110.175182

Zobrazit plný text záznamu

F 15845, a new blocker of the persistent sodium current prevents consequences of hypoxia in rat femoral artery

Autor: B Le Grand, B Vacher, Sylvie Sablayrolles, Arnaud Bocquet

Publikováno v: British Journal of Pharmacology. 161:405-415

BACKGROUND AND PURPOSE The persistent sodium current is involved in myocardial ischaemia and is selectively inhibited by the newly described 3-(R)-[3-(2-methoxyphenylthio-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine bromhydrate (F 1584

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::979bab04ca39f58758ae9fe4e372d191
https://doi.org/10.1111/j.1476-5381.2010.00912.x

Zobrazit plný text záznamu

Effects of a new PAR1 antagonist, F 16618, on smooth muscle cell contraction

Autor: Bruno Le Grand, Sylvie Sablayrolles, Luc De Vries, Michel Perez, Robert Létienne, Arnaud Bocquet

Publikováno v: European Journal of Pharmacology. 611:60-63

This study evaluated the effects of two PAR1 antagonists on vessels contracted by SFLLR. ER 121958 antagonized the SFLLR-induced contraction on rat denuded superior mesenteric artery and pig coronary artery in a non-competitive manner (IC 50 values w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ca3784f5533f3cce76dbb34d1248b73
https://doi.org/10.1016/j.ejphar.2009.03.056

Zobrazit plný text záznamu

Protease-Activated Receptor-1 Mediates Thrombin-Induced Persistent Sodium Current in Human Cardiomyocytes

Autor: Stéphane N. Hatem, Alain Coulombe, Vincent Algalarrondo, Michel Perez, Christophe Pignier, Didier Cussac, Sylvie Sablayrolles, Bruno Le Grand, Caroline Pinet

Publikováno v: Molecular Pharmacology. 73:1622-1631

After the thrombus formation in cardiac cavities or coronaries, the serine protease thrombin is produced and can therefore reach the myocardial tissue by the active process of extravasation and binds to the G protein-coupled protease-activated recept

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c952800563b54e94a5117986392319b
https://doi.org/10.1124/mol.107.043182

Zobrazit plný text záznamu

3-(R)-[3-(2-methoxyphenylthio-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine bromhydrate (F 15845) prevents ischemia-induced heart remodeling by reduction of the intracellular Na+ overload

Autor: Bruno Le Grand, Monique Bernard, D. Feuvray, Amaria Darmellah, Robert Létienne, Bruno Vié, Sylvie Sablayrolles, Bernard Vacher

Publikováno v: The Journal of pharmacology and experimental therapeutics. 330(3)

The present study investigates whether 3-(R)-[3-(2-methoxyphenylthio-2-(S)-methylpropyl]amino-3,4-dihydro-2H-1,5-benzoxathiepine bromhydrate (F 15845), a new, persistent sodium current blocker, can reduce the ischemic Na(+) accumulation and exert sho

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::feb78b5732df74b3ebc488fc53013d4f
https://pubmed.ncbi.nlm.nih.gov/19515969

Zobrazit plný text záznamu

Drug evaluation: dronedarone, a novel non-iodinated anti-arrhythmic agent

Autor: Sylvie, Sablayrolles, Bruno, Le Grand

Publikováno v: Current opinion in investigational drugs (London, England : 2000). 7(9)

sanofi-aventis (formerly Sanofi-Synthelabo) is developing the oral class III anti-arrhythmic agent dronedarone (Multaq) for the potential treatment and prevention of atrial fibrillation. In June 2005, sanofi-aventis submitted EU and US filings for at

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::bdea1a30304ec8bde0e887b67488aae3
https://pubmed.ncbi.nlm.nih.gov/17002263

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání